



ABN 53 075 582 740

## ASX ANNOUNCEMENT

22 June 2020

---

### EXECUTIVE CHAIRMAN – NEW CONSULTANCY AGREEMENT

Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company announced today that Dr Errol De Souza will continue in the role of Executive Chairman from 22 June 2020 to 30 June 2021 under a new Consultancy Agreement.

#### Material Terms of New Consultancy Agreement

In accordance with ASX Listing Rule 3.16.4, Bionomics makes the following disclosures in relation to the material terms of the new Consultancy Agreement between the Company and Dr Errol De Souza

<b>Position</b>	Executive Chairman
<b>Commencement Date</b>	22 June 2020
<b>Expiry Date</b>	30 June 2021
<b>Fixed Remuneration</b>	USD 21000 per month Reimbursement of up to USD18,000 for the cost of procuring Health Benefits in the US.
<b>Short Term Incentive (STI)</b>	Bonus potential of 70% of Fixed Remuneration, up to USD176,400, as assessed by the independent NEDs against agreed financial, strategic and operational targets.
<b>Long Term Incentive (LTI)</b>	Subject to shareholder approval at the next general meeting of shareholders, the grant of 12 million Options under the Employee Equity Plan on the following terms; <ul style="list-style-type: none"><li>• issue price of A\$0.04 per Option (each Option convertible into one ordinary share);</li><li>• 6 million Options vest at A\$0.14c and 6 million Options vest at A\$0.24;</li><li>• all Options expire 5 years from the date of grant; and</li><li>• full vesting upon change of control and share consolidation provisions apply.</li></ul>
<b>Termination</b>	One month's written notice by either party.

#### FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
+61 8 8354 6181  
[jmoschakis@bionomics.com.au](mailto:jmoschakis@bionomics.com.au)

### **About Bionomics Limited**

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

[www.bionomics.com.au](http://www.bionomics.com.au)